Compare IMMR & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | CVRX |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 253.2M |
| IPO Year | 1999 | 2021 |
| Metric | IMMR | CVRX |
|---|---|---|
| Price | $7.07 | $9.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $12.25 | ★ $13.17 |
| AVG Volume (30 Days) | ★ 556.4K | 275.1K |
| Earning Date | 12-15-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | $55,969,000.00 |
| Revenue This Year | $988.71 | $11.32 |
| Revenue Next Year | $109.72 | $18.58 |
| P/E Ratio | $3.48 | ★ N/A |
| Revenue Growth | ★ 338.21 | 18.44 |
| 52 Week Low | $5.65 | $4.30 |
| 52 Week High | $10.72 | $18.55 |
| Indicator | IMMR | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 54.37 |
| Support Level | $5.65 | $8.37 |
| Resistance Level | $7.29 | $10.28 |
| Average True Range (ATR) | 0.32 | 0.69 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 89.02 | 76.44 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.